Science and Policy Advisory Council
The Science and Policy Advisory Council provides a disruptive force in our dynamic healthcare forum through expert observations and recommendations on DIA's content strategies, essential research questions, key opinion leaders, collaboration partners, and trends affecting the future life sciences landscape.
Clark Golestani is an investor, advisor with a focus on the healthcare, life science and TMT sectors. Golestani currently serves as the Managing Director of C Sensei Group, LLC, as a senior advisor to New Mountain Capital, an investment advisor to The CXO Fund, and as a special advisor to the Dean at the University of Texas at Austin, Dell Medical School. He serves as chairman of the board for Sparta Systems, and as an independent director on the board for CIOX Health, eMids, TruU, Inc., UMUC/Ventures, and Zapata Computing. Golestani retired from Merck in 2018 as the President, Emerging Businesses and Global CIO. Prior to Merck, he was a principal with Oracle. He attended the Massachusetts Institute of Technology Sloan School of Management.
Peter Sorger is the Otto Krayer Professor of Systems Pharmacology at Harvard Medical School. He received his AB from Harvard College and PhD from Trinity College, Cambridge University U.K., working under the supervision of Hugh Pelham. He trained as a postdoctoral fellow at the University of California, San Francisco with Harold Varmus and Andrew Murray. Prior to coming to HMS Peter served as a Professor of Biology and Biological Engineering at MIT. Sorger was cofounder of Merrimack Pharmaceuticals and Glencoe Software and is an advisor to multiple public and private companies and research institutes in the US, Europe and Japan.
Andy earned his MD from Brown Medical School and completed residency and fellowship training in Anatomic Pathology and Molecular Genetic Pathology from Stanford University. He completed a PhD in Biomedical Informatics from Stanford University, where he developed one of the first machine-learning based systems for cancer pathology. He’s been certified by the American Board of Pathology in Anatomic Pathology and Molecular Genetic Pathology. Prior to co-founding PathAI, he was on the faculty of Harvard Medical School in the Department of Pathology at Beth Israel Deaconess Medical Center. He has published over 110 papers in the fields of cancer biology, cancer pathology, and biomedical informatics.
Jennifer Levin Carter
Dr. Jennifer Levin Carter is a Partner at Sandbox Healthcare and the Blue Venture Fund. She currently serves on the Board and/or as a strategic advisor to multiple public and private precision medicine, healthcare services, digital health and life science companies. Prior to Sandbox, she founded TrialzOWN™, Inc., a healthcare company in stealth, and was CEO until its prelaunch acquisition by the Flagship Pioneering company. Jennifer was the Founder and President of N-of-One®, Inc, serving as acting-CEO from 2008-2012, and CMO from 2012-2019. She holds a BS in Molecular Biophysics and Biochemistry from Yale University, an MD from Harvard Medical School, an MPH from Harvard School of Public Health, and an MBA from the Sloan School at MIT.
Andy Coravos (@andreacoravos) is the CEO/co-founder of HumanFirst, a health-tech company that helps leading pharma and biotech companies plan for and deploy effective hybrid and at-home clinical trials. In addition to her work with HumanFirst, Coravos is also a research collaborator at the Harvard-MIT Center for Regulatory Sciences. Formerly, she served as an Entrepreneur in Residence at the FDA working in the Digital Health Unit (DHU), focusing on the Pre-Cert program and policies around software-as-a-medical-device and AI/ML. Coravos currently serves on the Board of the Digital Medicine Society (DiMe), and is an advisor to the Biohacking Village at DEF CON.
Nancy A. Dreyer
Fellow of DIA
Nancy Dreyer is Adjunct Professor of Epidemiology at the Univ. of North Carolina, a Trustee of Brandeis Univ. and was Chief Scientific Officer at IQVIA Real World Solutions. Recently retired from full-time employment, she maintains an active career consulting, teaching for the International Society of Pharmacoepidemiology (ISPE) and the ISPOR RWE leadership team, and publishing. She has helped advance global use of real-world evidence by medicinal product regulators, with her work cited in guidelines in the US, Europe, and China. She is a member of DIA's Scientific and Policy Advisory Council and is a fellow of both DIA and ISPE.
Susanne Gronen leads the Data Science organization in Development for Astellas. Her responsibilities include Biostatistics, Statistical Programming, Data Management and Medical Writing for Clinical Development and Medical Affairs. Over the last few years, Susanne has fully globalized her organization. Under her leadership, the department has built a Central Monitoring & Data Surveillance team in support of the overall risk based monitoring effort. Susanne has spent most of her career in data science functions. Prior to joining Astellas, she worked at a global CRO as a statistician. Susanne holds an MSc in Statistics from the University of Dortmund, Germany.
Natalija Jovanovic was most recently the Global Head of Digital / Chief Digital Officer at Sanofi Pasteur Vaccines, a $7-billion division of Sanofi. She was leading an international cross-functional team in both driving digital innovation and ensuring operational IT excellence. Previously, she delivered a wide range of digital and analytics solutions at global insurer AIG as part of AIG Science team, and as VP of Innovation at Brown Brothers Harriman. She brings consulting and business strategy experience from McKinsey and is a member of advisory and scientific councils for multiple organizations and startups. Natalija holds a PhD in electrical engineering from MIT, where she worked on automotive and aerospace photonic power solutions.
Yeul Hong Kim
Yeul Hong Kim, MD, PhD, is a Professor in the Department of Internal Medicine at the Korea University College of Medicine in Seoul. He is actively involved in cancer genomic research, using circulating tumor DNA, for lung and gastrointestinal cancers. His primary area of interest is in the development of new therapies in gastric cancer, colon cancer, and other gastrointestinal cancers including pancreatic cancer and biliary cancer. Dr. Kim has also served as President of the Asian Clinical Oncology Society since 2016. He is also Director of the K-MASTER Cancer Precision Medicine Diagnosis and Treatment Enterprise, a cancer precision medicine project funded by the Korea Ministry of Health and Welfare.
Fellow of DIA
Sandra Milligan is the executive vice president and head of Research and Development, Organon, focused on improving the everyday health of every woman. Prior to this role, she served as senior vice president and head of Global Regulatory Affairs and Clinical Safety (GRACS), consisting of global Regulatory, Safety and CMC functions at Merck & Co., Inc. From 2011 to 2017, Sandy served on the board of directors and executive committee of the DIA. In 2017, Sandra was recognized as a DIA Fellow and was appointed to the Science Advisory Council in 2018. She is a graduate of George Washington University School of Medicine and Georgetown University Law Center.
Michael Rosenblatt, MD, Senior Partner at Flagship Pioneering, has advanced academic and biopharmaceutical research and development throughout his career. He was previously Chief Medical Officer for Merck, after serving as Dean of Tufts Medical School. Formerly, he was Ebert Professor of Molecular Medicine and Minot Professor at Harvard. He served as President of Beth Israel Deaconess Medical Center and as Director of the Harvard-MIT Division of Health Sciences & Technology. He is on the board of several life sciences companies, and on the Harvard Medical School Board of Fellows and research advisory committees of the Massachusetts General, Brigham and Women’s, and Boston Children’s Hospitals. He earned his MD from Harvard Medical School.
Birgit more than 15 years’ experience in R&D. As a bioengineer by training she is passionate about applying computational approaches (machine learning/AI as well as Systems Biology/Systems Pharmacology) to drug discovery and development. Currently, she serves a Global Head of Modeling and Simulation, PK Sciences at Novartis. She received her Diplom Ingenieur (MSc) in Chemical Engineering from the Technical University in Karlsruhe, Germany, and her PhD in Biological Engineering from the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg. She was a post-doctoral fellow in the laboratories of Douglas Lauffenburger and Peter Sorger in the Biological Engineering Department at MIT.
Dr. Ling Su is a Research Fellow in Shengyang Pharmaceutical University Yeehong Business School and a Venture Partner in Lilly Asia Ventures (LAV). He has 30 years of experience in drug regulatory and development. He had worked in various R&D management positions in the pharma industry, including Medical Director at MSD, Pharma Development Director at Roche, VP for Clinical Research Asia Pacific at Wyeth, and SVP and Head of Pharma Development China at Novartis. Prior to that, he worked in the Chinese regulatory agency and CDER, US FDA. He is a Fellow of DIA and was the President of DIA (2012-2013). Ling holds BS in pharmacology from Shanghai Medical University and PhD in Epidemiology from University of North Carolina at Chapel Hill, USA.
As Commissioner, Dr. Califf oversees the full breadth of the FDA portfolio and execution of the Federal Food, Drug, and Cosmetic Act and other applicable laws. This includes assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices; the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation; and the regulation of tobacco products. Dr. Califf has had a long and distinguished career as a physician, researcher, and leader in the fields of science and medicine.
Sandra Horning, MD is currently a co-founder and advisor for EQRx, a biotechnology company focused on creating innovative medicines at lower prices. Previously she served as CMO and Head of Global Product Development at Genentech/Roche from 2014 to 2019. Over the course of a decade, she oversaw the approval of 15 new medicines across a variety of diseases. Prior to joining Genentech, she spent more than 20 years as a Professor of Medicine, Oncology and Blood and Bone Marrow Transplantation at Stanford University School of Medicine, where she remains an Emerita Professor. Dr. Horning received her M.D. from University of Iowa School of Medicine and completed her post-graduate fellowship in Oncology and Cancer Biology at Stanford University.